Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Several morphology- and polymerase chain reaction (PCR)-based methods for chromosome 1p 19q deletion status assessment are available. Important prerequisites for all molecular techniques concern tissue quality and selection of regions of interest. The most common methods for diagnostic 1p 19q assessment are fluorescence in situ hybridization and PCR-based microsatellite analysis. While the latter requires the use of autologous blood samples, more advanced techniques such as array comparative genomic hybridization, multiplex ligation-dependent probe amplification or real-time PCR are independent from autologous DNA samples. However, due to high technical demand and experience required their applicability as diagnostic tests remains to be shown. On the other hand, chromogenic in situ hybridization evolves as attractive alternative to FISH. Herein, the available test methods are reviewed and outlined, their advantages and drawbacks being discussed in detail.

[1]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[2]  P. Maxwell,et al.  Fluorescence (FISH) and chromogenic (CISH) in situ hybridisation in prostate carcinoma cell lines: comparison and use of virtual microscopy , 2008, British journal of biomedical science.

[3]  Zhi-Hai Peng,et al.  Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer. , 2005, World journal of gastroenterology.

[4]  Martin Braun,et al.  The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches , 2011, BMC Cancer.

[5]  H. Heinzl,et al.  Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. , 2010, Clinical neuropathology.

[6]  B. Scheithauer,et al.  Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features , 2003, Journal of neuropathology and experimental neurology.

[7]  B. Feuerstein,et al.  Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas , 2005, Genes, chromosomes & cancer.

[8]  S. Dacic,et al.  The Importance of 10q Status in an Outcomes-Based Comparison Between 1p/19q Fluorescence In Situ Hybridization and Polymerase Chain Reaction–Based Microsatellite Loss of Heterozygosity Analysis of Oligodendrogliomas , 2012, Journal of neuropathology and experimental neurology.

[9]  K. Roth,et al.  Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas , 2004, Journal of neuropathology and experimental neurology.

[10]  C. Miller,et al.  Gone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade , 2011, Brain pathology.

[11]  Wei Wu,et al.  Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers , 2012, The Journal of pathology.

[12]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[13]  T. LaFramboise,et al.  Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances , 2009, Nucleic acids research.

[14]  David Scheie,et al.  Fluorescence In Situ Hybridization (FISH) on Touch Preparations: A Reliable Method for Detecting Loss of Heterozygosity at 1p and 19q in Oligodendroglial Tumors , 2006, The American journal of surgical pathology.

[15]  A. Sapino,et al.  A “Weighted” Fluorescence In Situ Hybridization Strengthens the Favorable Prognostic Value of 1p/19q Codeletion in Pure and Mixed Oligodendroglial Tumors , 2013, Journal of neuropathology and experimental neurology.

[16]  M. Rosenblum,et al.  Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity , 2012, Acta Neuropathologica.

[17]  S. Savola,et al.  Multiplex Ligation-dependent Probe Amplification (MLPA) in Tumor Diagnostics and Prognostics , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[18]  R. Stupp,et al.  Molecular diagnostics of gliomas: the clinical perspective , 2010, Acta Neuropathologica.

[19]  Cisca Wijmenga,et al.  Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. , 2005, Cancer research.

[20]  H. Budka,et al.  Fluorescent In Situ Hybridization on Isolated Tumor Cell Nuclei: A Sensitive Method for 1p and 19q Deletion Analysis in Paraffin-Embedded Oligodendroglial Tumor Specimens , 2003, Modern Pathology.

[21]  P. Eilers,et al.  Multiplex Ligation‐Dependent Probe Amplification for the Detection of 1p and 19q Chromosomal Loss in Oligodendroglial Tumors , 2005, Brain pathology.

[22]  P. Burger,et al.  Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss , 2006, Journal of neuropathology and experimental neurology.

[23]  M. J. van den Bent,et al.  New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. , 2013, European journal of cancer.

[24]  D. Ruiter,et al.  Multiplex Ligation-Dependent Probe Amplification for the Detection of Chromosomal Gains and Losses in Formalin-Fixed Tissue , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[25]  M. Prados,et al.  Gliosarcoma arising from an oligodendroglioma (oligosarcoma). , 2013, Clinical neuropathology.

[26]  C. Fuller,et al.  Fluorescence In Situ Hybridization (FISH) in Diagnostic and Investigative Neuropathology , 2002, Brain pathology.

[27]  J. Uhm An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[28]  J. Eshleman,et al.  Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis. , 2011, The Journal of molecular diagnostics : JMD.

[29]  Sridhar Ramaswamy,et al.  Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.

[30]  Robert B. Jenkins,et al.  Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.

[31]  A. Verma MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[32]  T. Koschny,et al.  Comparative genomic hybridization pattern of non-anaplastic and anaplastic oligodendrogliomas--a meta-analysis. , 2006, Pathology, research and practice.

[33]  P. Wesseling,et al.  Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. , 2006, The Journal of molecular diagnostics : JMD.

[34]  J. Hainfellner,et al.  Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well‐Preserved Histomorphology, Immunohistochemistry and Nucleic Acids , 2010, Brain pathology.

[35]  R. Mirimanoff,et al.  Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. , 2009, Neuro-oncology.

[36]  P. Ambros,et al.  Detection of 1p36 deletions in paraffin sections of neuroblastoma tissues , 1993, Genes, chromosomes & cancer.

[37]  H. Heinzl,et al.  Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers , 2013, Clinical neuropathology.

[38]  A. von Deimling,et al.  Chromogenic in situ Hybridization is a Reliable Alternative to Fluorescence in situ Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin‐Embedded Gliomas , 2013, Brain pathology.

[39]  Emmanuel Barillot,et al.  BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas , 2007, International journal of cancer.

[40]  M. J. van den Bent,et al.  Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Caroline Dehais,et al.  Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. , 2014, Neuro-oncology.

[42]  J. Rey,et al.  Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. , 2009, Cancer genetics and cytogenetics.

[43]  M. Gelabert-González,et al.  Primary central nervous system lymphoma. , 2013, Neurologia.

[44]  G. Barnett,et al.  Characterization of the 1p/19q Chromosomal Loss in Oligodendrogliomas Using Comparative Genomic Hybridization Arrays (CGHa) , 2004, Journal of neuropathology and experimental neurology.

[45]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[46]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[47]  Arie Perry,et al.  Molecular Diagnostics in Central Nervous System Tumors , 2005, Advances in anatomic pathology.

[48]  K. Hoang-Xuan,et al.  Chromosome 1p loss evaluation in anaplastic oligodendrogliomas , 2008, Neuropathology : official journal of the Japanese Society of Neuropathology.

[49]  M. Nikiforova,et al.  1p/19q testing has no significance in the workup of glioblastomas , 2013, Neuropathology and applied neurobiology.

[50]  K. Hoang-Xuan,et al.  Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. , 2008, Neuro-oncology.

[51]  F. Ducray,et al.  SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas , 2012, PloS one.

[52]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[53]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[54]  Yi-Hong Zhou,et al.  Detection of 1p19q Deletion by Real-Time Comparative Quantitative PCR , 2012, Biomarker insights.

[55]  Andrea Ferreira-Gonzalez,et al.  Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. , 2003, Genomics.

[56]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Eshleman,et al.  Molecular Diagnosis of Oligodendroglioma in Paraffin Sections , 2003, Laboratory Investigation.

[58]  K. Aldape,et al.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. , 2001, The American journal of pathology.

[59]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. von Deimling,et al.  Molecular Genetic Analysis of Oligodendroglial Tumors , 2005, Journal of neuropathology and experimental neurology.

[61]  R. McLendon,et al.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. , 1999, The American journal of pathology.

[62]  Eric S. Lander,et al.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays , 2000, Nature Biotechnology.

[63]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[64]  A. Iafrate,et al.  Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss , 2009, Clinical Cancer Research.

[65]  B. O'neill,et al.  Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens , 2011, Clinical Cancer Research.

[66]  J. Hainfellner,et al.  FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). , 2011, Clinical neuropathology.

[67]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[68]  C. Sarkar,et al.  Detection of Allelic Status of 1p and 19q by Microsatellite-based PCR Versus FISH: Limitations and Advantages in Application to Patient Management , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.